Scinai Immunotherapeutics (SCNI) Q2 2024 earnings summary

Executive summary

• Restructured €26.6M ($29M) EIB bank loan to equity, reducing debt to €250K and positioning to regain Nasdaq compliance by August 23, 2024.

• Focused on developing innovative VHH antibodies for autoimmune and infectious diseases and operating a CDMO unit for early-stage biologics projects.

• Strategic priorities include fast-tracking IL-17 development, expanding CDMO revenues, and risk-sharing R&D partnerships.

• Advanced NanoAb pipeline with positive preclinical results in psoriasis and regulatory feedback supporting Phase 1/2a trial in 2025.

Financial highlights

• R&D expenses for H1 2024 were $2.79M, down from $3.45M YoY, mainly due to lower salaries and subcontractor use.

• Marketing and G&A expenses fell to $1M from $2.3M YoY; financial expenses dropped to $0.53M from $1.5M.

• Net loss for H1 2024 was $4.48M, improved from $7.28M YoY; cash as of June 30, 2024, was $3.08M.

• CDMO revenues and a government grant helped reduce cash burn.

Outlook and guidance

• CDMO business unit guidance for 2024 is $1.25M in revenues, with expectations for material growth in coming years.

• Expects to regain Nasdaq compliance by August 23, 2024, following loan restructuring.

• Phase 1/2a clinical trial for anti-IL-17A/F NanoAb in plaque psoriasis planned for H2 2025, with readout in 2026.

• Ongoing optimization of NanoAb administration schedule to extend therapeutic effect.